Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
118
Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited - Updates on AC Immune's Pipeline and Technology Platforms to be presented at AAIC in Chicago

Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited - Updates on AC Immune's Pipeline and Technology Platforms to be presented at the Alzheimer's Association International Conference in Chicago

Lausanne, Switzerland, July 17, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced that the second Phase 3 (CREAD 2) clinical trial of crenezumab, AC Immune's anti-Abeta antibody candidate for treatment of Alzheimer's disease, conducted by its partner Genentech, a member of the Roche Group, has completed global recruitment.

Prof. Andrea Pfeifer, CEO of AC Immune , commented: "We are very happy that the CREAD 2 recruitment has been completed ahead of schedule. This clearly shows the strong commitment of our partner Roche/Genentech to the development of crenezumab as a potential disease-modifying therapy for Alzheimer's disease - one of society's biggest healthcare challenges."

The following updates on AC Immune's advancement of its in-house and partnered product candidates and technology platforms including crenezumab, will be presented at the Alzheimer's Association International Conference (AAIC © 2018). The conference is the largest international meeting dedicated to advancing dementia science and takes place in Chicago, US, from July 22 nd to 26 th , 2018:

Program and Collaborator Presentations and Timing
Tau PET Imaging agent / Piramal/InviCRO  Clinical Update: 18f-PI-2620, a Next Generation Tau PET Agent Evaluated in Subjects with Alzheimer's Disease and Progressive Supranuclear Palsy   Poster - July 21 / 12 :30pm - 1:45pm (CDT)   Session: IC-P-220 / Hall: F1
Crenezumab / Genentech/Roche  Baseline characteristics from a phase 3 trial of crenezumab in prodromal to mild Alzheimer's disease (CREAD)   Oral presentation - July 22 / 8:45pm - 9:00pm (CDT) Session: O1-02-04 / Room: 183
Alpha-synuclein PET tracers / AC Immune  Novel alpha-synuclein Positron Emission Tomography (PET) tracers for the Diagnosis of Parkinson's Disease   Oral presentation - July 25 / 3:15pm - 3:30pm (CDT)   Session: DT-01-06 / Hall: W375 E
Crenezumab / Genentech  Target Engagement in an AD Trial: Crenezumab Lowers Aß Oligomer Levels in CSF   Oral presentation - July 25 / 4:45pm - 5:00pm (CDT) Session: DT-01-03 / Hall: W375 E

About Crenezumab Crenezumab is an anti-Abeta antibody discovered by AC Immune using its SupraAntigen(TM) technology platform and out-licensed to Genentech, a member of the Roche group, in 2006 as a potential therapy for Alzheimer's disease. Crenezumab is a fully humanized IgG4 monoclonal antibody that binds all forms of misfolded Abeta proteins, but especially to Abeta oligomers, to prevent and break up Abeta aggregation and promote Abeta disaggregation. The IgG4 subclass has reduced effector function, allowing microglia to clear Abeta from the brain while minimizing an inflammatory response.

Roche/Genentech is currently evaluating the clinical efficacy and safety of crenezumab in two Phase 3 clinical trials, CREAD 1 and 2, in 750 participants each trial with prodromal or mild Alzheimer's disease, which started in the first quarter of 2016 and the first quarter of 2017, respectively. CREAD 1 was fully recruited in the fourth quarter of 2017 and CREAD 2 completed global recruitment in July 2018. In addition, crenezumab was chosen by an international panel of experts, including the US National Institutes of Health, for use in a first-ever prevention trial in Alzheimer's disease in a large extended family in Colombia (API ADAD) in 2012.

About AC Immune AC Immune is a clinical-stage Swiss-based biopharmaceutical company, listed on Nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune's two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline features nine therapeutic and three diagnostic product candidates - with five product candidates currently in clinical trials. The most advanced of these is crenezumab, a humanized anti-amyloid-ß monoclonal IgG4 antibody that targets monomeric and aggregated forms of amyloid-ß, with highest affinity for neurotoxic oligomers. Crenezumab is currently in two Phase 3 clinical studies for AD, under a global program conducted by the collaboration partner Genentech (a member of the Roche Group). Other collaborations include Biogen, Janssen Pharmaceuticals, Nestlé Institute of Health Sciences, Piramal Imaging and Essex Bio-Technology.

Forward looking statements This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information-Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

For further information, please contact:

In Europe Beatrix Benz AC Immune Corporate Communications Phone: +41 21 345 91 34 E-mail: beatrix.benz@acimmune.com In the US Lisa Sher AC Immune Investor Relations Phone: +1 970 987 26 54 E-mail: lisa.sher@acimmune.com  
Nick Miles/Toomas Kull Cabinet Privé de Conseils s.a. Phone: +41 22 552 46 46 E-mail: miles@cpc-pr.com   kull@cpc-pr.com   Ted Agne The Communications Strategy Group Inc. Phone: +1 781 631 3117 E-mail: edagne@comstratgroup.com

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Five SEAL Medal of Honor Signatures, One Charity Lot

Updated Category News Views 35

A single rifle can carry a staggering amount of meaning when the names on it belong to all five living U.S. Navy SEAL Medal of Honor recipients. Rock Island Auction Company plans to offer that one-of-a-kind custom precision rifle during its December 4–6, 2026 Premier Firearms Auction, and the financial arrangement is unusually clean: 100% of proceeds are slated for the...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
TDH's First-Half Revenue Grew, but Margins Vanished

Updated Category News Views 91

A rental business can add tenants and still march backward, and TDH Holdings just demonstrated the ugly math. For the six months ended June 30, 2026, revenue from continuing operations rose 26.45% to $0.74 million. That is the pleasant number, and it deserves exactly one polite nod. Everything beneath it looks far less comfortable: costs climbed faster than revenue, gross...

Continue Reading
Adecco Finds AI Value Depends on Better Work Redesign

Updated Category News Views 74

A shiny AI license is not a productivity strategy, and Adecco's latest workforce survey puts some hard numbers behind that irritation. The company surveyed 40,500 workers in 36 countries for its seventh Global Workforce of the Future report, released November 19, 2026. Its central finding is disarmingly sensible: AI produces more when companies rebuild the work around it...

Continue Reading
Alphabet Lawsuit Puts Gemini Delays Under a Microscope

Updated Category News Views 151

July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...

Continue Reading
First Horizon Opens Its Charlotte Office in South End

Updated Category News Views 14

A Building Is Not a Balance Sheet Charlotte got a fresh First Horizon sign at 110 East Boulevard on Nov. 19, 2026, and that is a sensible move, not a magic trick. The bank has officially opened a corporate office in the city’s South End neighborhood, positioning the team to develop client relationships across the Charlotte area and broaden its regional footprint. That...

Continue Reading
Makera A1S Tests the Desktop CNC Metal-Cutting Promise

Updated Category News Views 84

Aluminum chips are where desktop-machine marketing stops bluffing, and Makera is leaning right into that test with the A1S. The company opened global pre-orders on November 18 for a machine aimed squarely at the awkward middle ground: users who have outgrown entry-level hobby gear but do not have room, budget, or patience for a full industrial setup. That is a real market...

Continue Reading
PenFed’s Toys for Tots Drive Targets Holiday Gift Gaps

Updated Category News Views 69

A missing present under a tree is not a statistic anybody ought to glide past. PenFed Credit Union has opened its annual Toys for Tots collection across Washington-region branches, taking new, unwrapped toys through December 8 at 1:00 p.m. ET. The useful detail, and frankly the one worth remembering when people default to buying the easiest shiny thing on a shelf, is...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 43

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
Royce Global Trust's Discount Is Still the Whole Debate

Updated Category News Views 90

A $3.03 gap is staring investors right in the face. As of October 31, 2026, Royce Global Trust carried a net asset value of $17.51 per share while the market price sat at $14.48. That works out to roughly a 17.3% discount to NAV, and with a closed-end fund, that discount is not some footnote shoved under the table. It is a major part of the return story, good or bad. The...

Continue Reading

Top 5 Most Recently Viewed Articles

Light AI Secures Major Over-Allotment and Begins Trading on Cboe

Updated Category News Views 160

Light AI Announces Successful Closure of Over-Allotment Option Light AI Inc. (formerly known as Mojave Brands Inc.) (CBOE CA: ALGO) is thrilled to share recent developments regarding its over-allotment option, which saw a successful full exercise by the Agents. This step resulted in the purchase of an additional 2,757,000 units, amounting to an impressive gross proceeds...

Continue Reading
U.S. Stock Market Futures Decline Ahead of Key Economic Data

Updated Category News Views 290

U.S. Stock Market Futures Show Caution Ahead of Economic Reports Recently, U.S. stock index futures have taken a downward turn as traders adopt a cautious stance. With a series of economic data reports set to be released this week, the financial markets are bracing for potential impacts on the Federal Reserve's monetary policy in the near future. Market Performance in...

Continue Reading
RUSH's 2026 Tour: Celebrating Legacy and New Beginnings

Updated Category News Views 329

RUSH's 2026 Tour: A Celebration of Music and Legacy Geddy Lee and Alex Lifeson are set to celebrate over 50 years of RUSH's musical journey as they announce a special headline tour for 2026, named the Fifty Something Tour. This tour not only commemorates the incredible music and legacy of RUSH, but also pays tribute to their late drummer and lyricist Neil Peart, whose...

Continue Reading
Star Hats & Embroidery Shines on CBS National Network

Updated Category News Views 126

Star Hats & Embroidery Takes Center Stage on National Television Star Hats & Embroidery is proud to announce its recent television features that highlight the innovative products and services they offer. Following an exciting showcase on CBS's Las Vegas Now Lifestyle TV Show, the brand has appeared in numerous segments across the nation, captivating audiences everywhere....

Continue Reading
Celebrate Culture and Community at Ohkay Hotel's Lowrider Show

Updated Category News Views 350

Celebrate the Return of the Lowrider Phenomena The excitement is building as the Lowrider Phenomena Show rolls back into Ohkay Hotel Casino, promising an unforgettable day filled with stunning custom rides, electrifying live entertainment, and family-friendly activities. This eagerly anticipated event is free and welcomes everyone to partake in the festivities. A Vibrant...

Continue Reading